APC
EBS icon

Aspire Private Capital’s Emergent Biosolutions EBS Stock Holding History

Aspire Private Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-18
Closed -$1K – 566
2018
Q4 		$1K Buy
+18
New +$1.16K ﹤0.01% 456

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aspire Private Capital's EBS Position: Q1 2019 in Review

Aspire Private Capital sold out of Emergent Biosolutions (EBS) in Q1 2019, closing a stake of 18 shares — an estimated $1K sold.

Aspire Private Capital first reported a position in EBS in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2019.

  • Aspire Private Capital reported no remaining Emergent Biosolutions position as of Q1 2019 after selling out during the quarter.
  • Aspire Private Capital sold 18 Emergent Biosolutions shares in Q1 2019, an estimated $1K.
  • Aspire Private Capital first reported a position in Emergent Biosolutions in Q4 2018 and held it in 1 quarter.
  • Aspire Private Capital's Emergent Biosolutions position peaked at $1K in Q4 2018.
  • 272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2019.

Based on Aspire Private Capital's 13F filing for Q1 2019, filed 13 May 2019.